Monday, June 12, 2006

Avigen Announces Approval for AV411 Phase (Diabetes Mellitus) IIa Trial

Avigen Announces Approval for AV411 Phase IIa Trial
[Press Release] PR Newswire via Yahoo! Finance - Jun 12 5:00 AM
Avigen, Inc. today announced approval to initiate a Phase IIa exploratory therapeutic clinical trial with AV411 at the Royal Adelaide Hospital in Adelaide, Australia to assess safety, tolerability and preliminary indication of efficacy in neuropathic pain patients.Save to My Web

Green Tea And The 'Asian Paradox'
Science Daily - Jun 06 3:50 PM
There is a lower incidence of cardiovascular disease and cancer in Asia where people smoke heavily, which may be accounted for by high consumption of tea, particularly green tea.Save to My Web

BYETTA(R) Extension Study Shows Sustained Improvements in Blood Glucose Control and Progressive Weight Loss After Two
[Press Release] PR Newswire via Yahoo! Finance - 2 hours, 15 minutes ago
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced two-year study results showing that BYETTA injection sustained improvements in blood sugar control and reduced body weight in people with type 2 diabetes who previously did not achieve adequate control of their blood sugar on common oral medications.Save to My Web

Workplaces need gyms for health - Jun 06 12:35 PM
Accra, June 6, GNA - Dr Francis Kwamin, Lecturer at University of Ghana Medical School on Tuesday called for the establishment of gymnasiums in workplaces to promote physical fitness as part of preventive measures against cardiovascular disease (CVDs).Save to My Web

New Study Shows an Innovative Mealtime Insulin Dosing Algorithm May Provide a Safe and Effective Alternative to
[Press Release] PR Newswire via Yahoo! Finance - Jun 12 5:00 AM
Results from a new study presented at the American Diabetes Association's 66th Annual Scientific Sessions found that a simple algorithm to adjust mealtime insulin based on pre-meal glucose patterns is just as effective as the more complex carbohydrate counting method -- a standard technique that many diabetes patients find difficult to use.Save to My Web

Amylin Pharmaceuticals Demonstrates Progress Across Diabetes and Obesity Portfolios at ADA 2006
[Press Release] PR Newswire via Yahoo! Finance - Jun 06 1:05 PM
Amylin Pharmaceuticals, Inc. today announced that data featuring its approved drugs and pipeline candidates will be presented at the 66th Annual Scientific Sessions of the American Diabetes Association being held in Washington, DC from June 9 to 13.Save to My Web

Diabetes Mellitus